NEW YORK (GenomeWeb) – Editas Medicine has signed an exclusive license agreement with Massachusetts General Hospital for CRISPR/Cas9 genome editing technology that purports to lower off-target effects and increase the number of available targets.
Registering provides access to this and other free content.
Already have an account?Login Now.
Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.
US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.
A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.
In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.
This webinar will cover recent advances in the use of CRISPR for generating animal models and cell lines.